Chorionic Gonadotrophin Injection IP 5000 IU Puretrig – description of the medicinal product
Chorionic Gonadotrophin Injection IP 5000 IU Puretrig Puretrig is considered a safe and at the same time effective tool to normalise the sexual function of men and women. It is a natural hormone responsible for the production of testosterone and oestrogen. If there is a lack of gonadotropin in the body, there will be a deficiency of sex hormones.
The hormone drug is natural, as it is extracted from the urine of pregnant women. The main purpose of GC is the treatment of diseases of the reproductive system.
In heavy sports, it is used to normalise the level of male hormones whose production decreases with prolonged courses of steroids.
The drug has useful properties:
- activates the work of the sex glands;
- increases testosterone levels;
- affects performance;
- reduces aggressiveness and irritability.
In addition, it has a therapeutic effect:
- at puberty in adolescence;
- stimulates ovulation and oestrogen synthesis;
- ensures the development of the placenta;
- applicable in case of infertility.
The body does not produce antibodies against human chorionic gonadotropin.
Dosage and directions for use
Release form Chorionic Gonadotrophin Injection IP 5000 IU Puretrig Puretrig – white powder 5000 IU. The kit includes a solvent, 0.9% sodium chloride, a clear colourless liquid in ampoules.
The solution needs to be collected and placed in a container with powder for mixing injections. Shaking is not recommended. It is not necessary to cook in advance, it is not intended for long-term storage in finished form.
The usual weekly dose is 500-3000 IU. But it is desirable to calculate the rate individually, depending on the age and symptoms of the patient. The injection is administered intramuscularly every other day. The course of GC does not exceed 6 weeks.
The biological activity of gonadotropin for the male body is 7-16 hours.
You cannot take the drug on your own. Only the treating physician or sports specialist can correctly prescribe the cycle.
The indications for taking a substance in sports pharmacology are determined on the basis of the steroid programmes of athletes:
- Taking one type of anabolic agent for short periods of up to 6 weeks does not require the introduction of GCs.
- Complex courses or courses with a duration of 8 to 12 weeks, post-cycle therapy should be administered.
- The first month of Trenbolone – CG put 500-1000 IU 2 times per week;
- Take steroids for several months: 1000-1500 IU every 4 days before PCT;
- Very long courses of anabolic steroids, more than a year: mandatory injections of 1000-1500 IU every other day all the time and before PCT.
It is necessary to carefully monitor the period of anabolic steroid activity in the body, as it is necessary to stop taking the hormone when no traces of chemistry remain.
Strict adherence to the recommendations makes the drug completely safe for health, as it is of natural origin. Violation of the established doses may have consequences in men in the form of androgenic reactions:
- hair loss;
- water retention
- prostatic hypertrophy;
- There are several contraindications to take:
- individual intolerance;
- kidney problems;
- diseases of the cardiovascular system;
- malignant tumours.
Women should be careful when taking this drug. For them it is not desirable to administer the drug during lactation, with thrombophlebitis, thromboembolism. Side effects for the female body are more complex: ovarian hyperstimulation, risk of formation and rupture of ovarian cysts, chest pain, stomach cramps, migraine, weight gain, fever, acne, irritability and nervousness, depression. Therefore, it is necessary to prescribe GC only for medical reasons.
List of references
- Fauser BCJM, Diedrich K, Devroey P. “Recombinant FSH versus urinary gonadotropins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome: a systematic review and meta-analysis.” Hum Reprod Update. 2007;13(5):433-440.
- Casper RF. “Gonadotropin therapy: a 20th-century history.” Fertil Steril. 2012;97(4):773-778.
- Filicori M, Cognigni GE, Taraborrelli S, et al. “Novel concepts of human chorionic gonadotropin: reproductive system interactions and potential in the management of infertility.” Fertil Steril. 2005;84(2):275-284.
- Bosch E, Broer S, Griesinger G, et al. “Recombinant LH supplementation in women with hypo-response to controlled ovarian stimulation during IVF/ICSI: a systematic review and meta-analysis.” Hum Reprod Update. 2014;20(4):607-621.
- European Recombinant Human Chorionic Gonadotropin Study Group. “Induction of final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction, with a combination of gonadotropin-releasing hormone agonist and recombinant human chorionic gonadotropin: a prospective randomized study.” Fertil Steril. 2000;74(4):S38-S45.